Metabolic impact of Darunavir monotherapy vs Atripla in HIV patients

• Research type

  Research Study

• Full title

  The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs).

• IRAS ID

  55062

• Contact name

  Julie Fox

• Sponsor organisation

  Guy's & St. Thomas' NHS Foundation Trust

• Eudract number

  2010-022120-72

• ISRCTN Number

  n/a

• Research summary

  This project aims to assess the potential long-term advantages of switching HIV patients from the standard therapy (Atripla) to a different regime of treatment (darunavir 800 mg / ritonavir 100 mg). This will be assessed by measuring Vitamin D levels, calcium and phosphate homeostasis (balance), kidney (tubular) function, bone turnover and bone mineralisation, and HIV disease progression in all the patients who take part in the study.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  10/H0715/50

• Date of REC Opinion

  12 Oct 2010

• REC opinion

  Further Information Favourable Opinion